Tomorrow’s therapies deserve next-generation dosage forms

 

 

 

The pharmaceutical industry is undergoing a profound transformation.

 

Emerging therapies—including peptides, proteins, nucleotides, exosomes, vaccines, hormones, and personalized medicines—are creating new challenges in terms of stability, dosing accuracy, reconstitution, and administration.

 

Tomorrow’s medicines require more than innovative molecules. They also require next-generation dosage forms capable of improving bioavailability, enabling faster dissolution, supporting lower and more precise doses, and advancing the future of personalized medicine.

 

At Lyophitech, we develop advanced freeze-drying processes that transform liquid formulations into stable, accurately dosed, and industrially scalable solid dosage forms.

 

Because freeze-drying should do more than preserve a drug.

 

It should enable the pharmaceutical dosage forms of tomorrow.

 

 

 

 

 

A new generation of pharmaceutical dosage forms

 

 

 

 

Our patented technology combines ultra-fast freezing into accurately dosed beads with precisely controlled dynamic freeze-drying.

 

The resulting beads represent a new generation of Multiparticulate Drug Delivery Systems (MDDS), designed to meet the demands of next-generation pharmaceuticals.

 

Using our proprietary HelixSpin® and RiverLine® technologies, every droplet is volumetrically controlled before being instantly frozen in a liquid nitrogen stream.

 

We produce highly uniform beads ranging from 2 to 4.5 mm, allowing active ingredient content to be tailored according to formulation requirements while minimizing the cumulative statistical dosing errors commonly associated with multi-unit dosage forms.

 

This approach creates lyophilized beads offering outstanding dose flexibility, while maintaining a robust, reproducible, and easily scalable manufacturing process.

 

 

 

 

Enabling the medicines of tomorrow

 

 

 

Our processes are designed for the most advanced pharmaceutical formulations, including:

• Therapeutic peptides

• Proteins

• Hormones

• Vaccines

• Nucleotides and oligonucleotides

• Exosomes and extracellular vesicles

• Sensitive biomolecules

• Orphan drugs

• High-potency and low-dose therapies

 

Ultra-fast freezing minimizes stress on fragile biomolecules, while dynamic freeze-drying preserves their integrity throughout the entire process.

 

Processing can be performed under a controlled atmosphere to reduce oxidation and protect oxygen-sensitive products.

 

 

 

 

A new approach to dosing

 

 

 

Future medicines require greater flexibility.

 

Our technology produces individual pharmaceutical units directly from a liquid formulation, with dosing accuracy controlled from the moment each bead is formed.

 

By adjusting droplet volume and formulation concentration, pharmaceutical developers can tailor the delivered dose while maintaining a simple, robust, and reproducible manufacturing process.

 

This approach is particularly well suited for low-dose products, high-value therapeutics, innovative medicines, and the growing demand for patient-centric dosage forms.

 

 

 

 

Designed for every patient

 

 

Pediatric medicines remain one of the pharmaceutical industry’s greatest challenges.

 

Drug doses must be accurately adapted to each patient’s age, weight, and therapeutic needs.

 

Our orally dispersible beads, ranging from 2 to 4.5 mm, enable highly accurate dosing while simplifying administration.

 

They provide an innovative solution for developing flexible oral dosage forms that are better suited for pediatric use and, more broadly, for personalized treatment strategies.

 

 

 

Dissolution tailored to every application

 

 

 

Thanks to their highly porous structure, our lyophilized beads exhibit a high specific surface area, enabling rapid interaction with the reconstitution medium.

 

The process can be optimized according to the intended application, including:

• Rapid reconstitution for products supplied in vials

• Fast dissolution for orally dispersible dosage forms

• Excellent dispersion for topical formulations

 

Each formulation is developed to achieve its target performance, whether rapid reconstitution, optimized bioavailability, or improved patient convenience.

 

 

 

Quality designed into the process

 

 

Pharmaceutical quality begins long before the final packaging step.

 

Our equipment includes 0.22 µm liquid nitrogen filtration, helping ensure a production environment that meets the stringent quality requirements of the pharmaceutical industry.

 

The entire process is developed according to GMP by Design principles, combining contained processing, controlled atmospheres, and complete control of critical freezing and freeze-drying parameters.

 

 

 

 

From formulation development to aseptic fill-finish

 

 

 

At Lyophitech, we support pharmaceutical companies that need to develop or optimize their freeze-drying process without investing immediately in internal development capabilities.

 

Our experts perform feasibility studies, optimize process parameters, and support scale-up through to industrial technology transfer.

 

Through our network of specialized partners, we can also integrate aseptic fill-finish operations within isolators, providing a seamless development pathway through to ready-to-fill vials.

 

We do not develop your drug.

 

We work alongside you to develop the process that will preserve, stabilize, and successfully industrialize it.

 

Because tomorrow’s therapies deserve a technology capable of unlocking their full potential.